АШУҮИС — Судалгааны мэдээлэл (CRIS)
Permanent URI for this communityhttps://library.mnums.edu.mn/handle/123456789/5001
Browse
4 results
Search Results
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, Results of HDV RNA detection in male seminal fluid and female cervical swab samples using RT-PCR(Mongolian Academy of Sciences, 2023-12-29) ;Saruul Enkhjargal ;Oyungerel Lkhagva-Ochir ;Anir Enkhbat ;Naranjargal DashdorjMongolia has an extremely high prevalence of hepatitis D virus (HDV), which leads to increased morbidity and mortality from hepatocellular carcinoma (HCC). HDV is the most severe form of chronic viral hepatitis (CVH). A recent study estimated that the prevalence of anti-HDV was 67.5% among hepatitis B surface antigen-positive cases in Mongolia. HDV infection is particularly prevalent in sexually active young people. The virus may be transmitted through sexual intercourse, and it is crucial to confirm this by detecting HDV RNA in semen and cervical swabs of patients with chronic hepatitis delta. This pilot study was conducted with 16 participants, including eight males and eight females. Viral RNA was isolated from the blood, male seminal fluid, and female cervical swab samples of all participants in the study. HDV RNA was quantified using RT-PCR in samples from blood, seminal fluid, and cervical swabs. This study found that the detection rate of HDV RNA differed between male and female samples, with 62.5% of seminal fluid samples in the male cohort being positive compared with 87.5% in the female cohort. The data shows a statistically significant difference between genders for the presence of HDVRNA in seminal fluid and cervical swabs (OR 0.238, 95% CI= 0.02-3.01). A significant correlation was found between blood HDV RNA quantity and HDV RNA presence status in seminal fluid and cervical swab samples, indicating a potential risk of sexual HDV transmission. The R2 values for semen and cervical swab samples were 0.1095 and 0.9755, respectively. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Treatment of Chronic HCV Infection with Direct Acting Antivirals(Mongolian National University of Medical Sciences, 2021-09-21) ;Bekhbold Dashtseren ;Zulkhuu Genden ;Odgerel Oidovsambuu ;Anir EnkhbatGanbolor JargalsaikhanObjectives: This study was conducted to discover the treatment outcome and side effects of chronic hepatitis C virus patients treated with Direct-Acting Antivirals (DAAs). Methods: Based on the Liver Center database, we studied the treatment effect of Sofosbuvir 400 mg/Ledipasvir 90 mg in 1109 patients with chronic hepatitis C virus infection during the time period from December 2015 to December, 2018. Results: In patients treated with Sofosbuvir/Ledipasvir, the sustained viral load (SVR12) was 97.9% (1086/1109) 12 weeks after the treatment. The SVR12 was 99.2% (845/851) in HCV-infected non-cirrhotic patients, 93.4% (241/258) in patients with cirrhosis, and 80% (8/10) among patients treated for liver cancer. The SVR12 (19/25) was lowered to 76% at 12 weeks of treatment with Sofosbuvir 400 mg/ Daclatasvir 60 mg in DAA-failure patients 23/1109 (2.07%). Conclusions: SVR12 rates in non-cirrhotic and cirrhotic patients were 99.2% and 93.4%, respectively, while it was 80% in liver cancer patients after DAA treatment. As for patients with viral relapse, 76% of them were successfully retreated with second-line DAA treatment. During the DAA treatment, only 17.6% of all patients had some adverse effects related to DAA treatment, thus, DAA treatment is suitable for Mongolian patients and has less adverse effects. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Impact of Hepatitis D Coinfection on the Hepatitis Flare during Chemotherapy for B-Cell Non-Hodgkin Lymphoma(Mongolian National University of Medical Sciences, 2020-04-01); ;Anir Enkhbat ;Delgerbat Boldbaatar ;Khishigjargal BatsukhAltankhuu MurdojObjectives: This study was conducted to determine the effect of Hepatitis B infection with or without D coinfection on the hepatitis flare associated with chemotherapy for B-Cell non-Hodgkin lymphoma. Methods: The hepatitis flare related to the chemotherapy for newly diagnosed B-Cell non-Hodgkin lymphoma was studied in HBV mono-infected and HBV and HDV coinfected patients between 2015 and 2018. Results: Nineteen HBsAg positive patients satisfied the inclusion criteria. In the group with the hepatitis flare, 14.3% were anti-HDV negative and 83.3% were anti-HDV positive (p<.006). Also, the hepatitis flare occurred in all patients where HDV-RNA was detected, while it had occurred in 60% of patients where HDV-RNA was not detected. Conclusion: The hepatitis flare related to chemotherapy occurred more frequently in B-Cell non-Hodgkin lymphoma patients coinfected with HBV and HDV without antiviral prophylaxis, especially when HDV-RNA was detected. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Anti-HCV, HBsAg Positive Incidences Among Patients Aged 40 Years and Over Diagnosed with B- Non-Hodgkin’s Lymphoma: A Comparison with General Population of Same Age(Mongolian National University of Medical Sciences, 2019-12-29); ;Delgerbat Boldbaatar ;Anir Enkhbat; Khishigjargal BatsukhObjectives: There are several risk factors contribute to the development of the B-cell Non-Hodgkin’s lymphoma (B-NHL) among which hepatitis B, hepatitis C virus (HBV, HCV) infection, as well as old age, are known to have a signi cant effect. Previous studies examining the relationship between HBV, HCV infection and B-NHL show inconsistent results in different endemic areas. Methods: We compared the hepatitis B surface antigen (HBsAg) and antibody against the HCV (anti-HCV) positive incidences among aged 40 years or older patients who have been newly diagnosed with B-NHL, between 2015 and 2018, to prevalence of hepatitis B and C virus infection in the general population of Mongolia in the same age by data of the general population in hepatitis screening and the results of previous studies on the Mongolian population. Results: A total of 187 patients, newly diagnosed with B-NHL ≥40years of age took part in our study. In case of these two groups, the prevalence of HBsAg in the B-NHL population was close to the general population while anti-HCV positive was signi cantly higher in the B-NHL group (p<.00001). Conclusion: Further studies are needed to clarify the reasons and contributing factors which result situations where the HBV prevalence among B-NHL patients and the general population are not signi cantly different.
